Korean J Urol.  2008 Apr;49(4):300-306.

Analysis of the Expression of Peroxiredoxin I in Human Bladder Cancer

Affiliations
  • 1Department of Urology, College of Medicine, Eulji University, Daejeon, Korea.
  • 2Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. wjkim@chungbuk.ac.kr

Abstract

PURPOSE: Peroxiredoxins(PRDXs) are antioxidant enzymes that play an important role on cell differentiation, proliferation and apoptosis. In this study, we investigated if the expression levels of PRDX I were related to bladder cancer.
MATERIALS AND METHODS
The mRNA level of PRDX I was examined via real time polymerase chain reaction(PCR) in 186 cancer specimens from patients with primary bladder cancer, 73 corresponding samples of normal looking bladder mucosae surrounding the cancer and 21 samples of normal bladder mucosae. We investigated the correlation between the expression levels of PRDX I and the clinico-pathological parameters of the 154 patients who could be followed up more than three years.
RESULTS
The expression levels of PRDX I in bladder cancer(0.73pg/ml) were significantly higher that that in the normal bladder mucosae (0.04 pg/ml)(p<0.01) or that in the corresponding normal bladder mucosae surrounding the cancer(0.38pg/ml)(p<0.01). The expression level of PRDX I was not significantly enhanced in the non-recurred(0.87pg/ml) superficial bladder tumor patients compared with the recurred superficial bladder tumor patients(0.63pg/ml), but it was significantly enhanced in the non-progressed(0.82pg/ml) patients compared with the progressed (0.50pg/ml) patients(p<0.05 for each).
CONCLUSIONS
An enhanced expression of PRDX I is strongly associated with the development of bladder cancer. Moreover, enhanced expressions of PRDX I are also positively associated with a low rate of progression of bladder cancer, and this might be useful as a marker for assessing progression in human bladder cancers.

Keyword

Peroxiredoxin I; Bladder tumor

MeSH Terms

Apoptosis
Cell Differentiation
Humans
Mucous Membrane
Peroxiredoxins
RNA, Messenger
Urinary Bladder
Urinary Bladder Neoplasms
Peroxiredoxins
RNA, Messenger

Reference

1.Popov Z., Hoznek A., Colombel M., Bastuji-Garin S., Lefrere-Belda MA., Bellot J, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 1997. 80:1472–81.
Article
2.Kausch I., Bohle A. Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol. 2001. 39:498–506.
3.Kausch I., Bohle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol. 2002. 41:15–29.
4.Finkel T., Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000. 408:239–47.
Article
5.Kolonel LN., Hinds MW., Nomura AM., Hankin JH., Lee J. Relationship of dietary vitamin A and ascorbic acid intake to the risk for cancers of the lung, bladder, and prostate in Hawaii. Natl Cancer Inst Monogr. 1985. 69:137–42.
6.Ohnishi S., Murata M., Kawanishi S. Oxidative DNA damage induced by a metabolite of 2-naphthylamine, a smoking-related bladder carcinogen. Jpn J Cancer Res. 2002. 93:736–43.
Article
7.Akcay T., Saygili I., Andican G., Yalcin V. Increased formation of 8-hydroxy-2′-deoxyguanosine in peripheral blood leukocytes in bladder cancer. Urol Int. 2003. 71:271–4.
Article
8.Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003. 15:247–54.
Article
9.Osada H., Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 2002. 21:7421–34.
Article
10.Halliwell B., Gutteridge JM., Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med. 1992. 119:598–620.
11.Chae HZ., Robison K., Poole LB., Church G., Storz G., Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzy- mes. Proc Natl Acad Sci U S A. 1994. 91:7017–21.
12.Prosperi MT., Ferbus D., Karczinski I., Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem. 1993. 268:11050–6.
13.Ishii T., Yamada M., Sato H., Matsue M., Taketani S., Nakayama K, et al. Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J Biol Chem. 1993. 268:18633–6.
Article
14.Prosperi MT., Apiou F., Dutrillaux B., Goubin G. Organization and chromosomal assignment of two human PAG gene loci: PAGA encoding a functional gene and PAGB a processed pseudogene. Genomics. 1994. 19:236–41.
Article
15.Lyu MS., Rhee SG., Chae HZ., Lee TH., Adamson MC., Kang SW, et al. Genetic mapping of six mouse peroxiredoxin genes and fourteen peroxiredoxin related sequences. Mamm Genome. 1999. 10:1017–9.
Article
16.Prosperi MT., Ferbus D., Rouillard D., Goubin G. The pag gene product, a physiological inhibitor of c-abl tyrosine kinase, is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress. FEBS Lett. 1998. 423:39–44.
17.Kinnula VL., Lehtonen S., Sormunen R., Kaarteenaho-Wiik R., Kang SW., Rhee SG, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol. 2002. 196:316–23.
Article
18.Lehtonen ST., Svensk AM., Soini Y., Paakko P., Hirvikoski P., Kang SW, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004. 111:514–21.
Article
19.Noh DY., Ahn SJ., Lee RA., Kim SW., Park IA., Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001. 21:2085–90.
20.Fujii J., Ikeda Y. Advances in our understanding of peroxi-redoxin, a multifunctional, mammalian redox protein. Redox Rep. 2002. 7:123–30.
Article
21.Yanagawa T., Ishikawa T., Ishii T., Tabuchi K., Iwasa S., Bannai S, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 1999. 145:127–32.
Article
22.Yanagawa T., Iwasa S., Ishii T., Tabuchi K., Yusa H., Onizawa K, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000. 156:27–35.
Article
23.Neumann CA., Krause DS., Carman CV., Das S., Dubey DP., Abraham JL, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003. 424:561–5.
Article
Full Text Links
  • KJU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr